Prosecution Insights
Last updated: April 19, 2026
Application No. 17/620,669

GENE CIRCUIT SIMULATING ARTIFICIAL NEURAL NETWORK AND CONSTRUCTION METHOD THEREFOR

Final Rejection §112
Filed
Dec 17, 2021
Examiner
NEGIN, RUSSELL SCOTT
Art Unit
1686
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
U Seak CHI
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
4y 1m
To Grant
89%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allow Rate
504 granted / 899 resolved
-3.9% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
45 currently pending
Career history
944
Total Applications
across all art units

Statute-Specific Performance

§101
25.1%
-14.9% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
7.4%
-32.6% vs TC avg
§112
18.0%
-22.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 899 resolved cases

Office Action

§112
DETAILED ACTION Comments The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claims 1-10 are pending and examined in the instant Office action. Withdrawn Rejections The 35 U.S.C. 112(b), written description, and first enablement rejections of the previous Office action are withdrawn in view of amendments filed to the instant set of claims on 23 December 2025. Claim Rejections - 35 USC § 112(a) - Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The following rejection is reiterated: Claims 1-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. 1. The claims recite a gene circuit (or method of construction a gene circuit) that performs the functions of an artificial neural network. It is not understood as to how a series of gene activations by promoters imitates an artificial neural network. 2. The specification does not disclose how to make a neural network. Figure 1 of the drawings illustrates a conceptualized neural network with sets of chain reactions of cascading promoters activating gene expressions of other promoters. However, the specification does not explain how this is a neural network. Figures 2 and 4 also illustrate that a plurality of input nodes interact with a plurality of hidden nodes, and a plurality of hidden nodes interact with a plurality of output nodes in artificial neural networks. The configuration illustrated in Figure 1 does not possess this property of an artificial neural network. In other words, in Figure 1, the gene expression acts in single downstream sets of reactions. 3. The prior art of Kalogirou et al. [Encyclopedia of Energy, 1st edition, 2004] illustrates in Figure 3 artificial neural networks, it is normal for hidden layers to interact with both preceding and following layers. 4. The claims do not teach how to use generate a gene circuit that imitates a neural network. While the specification and prior art explain how artificial neural networks work, the alleged imitated neural network of Figure 1 of the specification does not teach a plurality of input nodes interacting with a plurality of hidden nodes, and a plurality of hidden nodes interacting with a plurality of output nodes (i.e. that is typical of a neural network). In the absence of guidance from the application, it is unpredictable as to how to use of cascading networks of gene expression in Figure 1 to imitate an artificial neural network Such unpredictability yields UNDUE EXPERIMENTATION. In view of the above, it is the Examiner’s position that with the insufficient guidance and working examples and in view of unpredictability and the state of art, one of skill in the art could not make and/or use the invention with the claimed breadth without an undue amount of experimentation. Response to Arguments Applicant's arguments filed 23 December 2025 have been fully considered but they are not persuasive. Applicant argues that paragraph 30 of the specification describes how the gene circuit functions as a neural network. This argument is not persuasive because paragraph 30 of the specification describes cascading gene expression and promoter generation, which is not equivalent to an artificial neural network. Applicant argues that paragraph 6 of the specification describes the gene circuit imitates the function of an artificial neural network. This argument is not persuasive because paragraph 6 of the specification describes gene expression. Applicant argues that since paragraph 43 of the specification describes a correlation of 0.496 when predicting toxicity, the gene circuit is a successful artificial neural network. This argument is not persuasive because successful property prediction do not necessarily result from usage of an artificial neural network. Applicant argues that neural networks to not require bidirectional calculations. Bidirectional calculations are not cited in the aforementioned rejection statement. Applicant provides the general assertion that paragraph 32 of the specification discloses that the gene circuit imitating an artificial neural network can be modified to mimic other artificial neural network gene circuits, such as a recurrent neural network. However, applicant does not provide evidence or a description of how this is accomplished. E-mail Communications Authorization Per updated USPTO Internet usage policies, Applicant and/or applicant’s representative is encouraged to authorize the USPTO examiner to discuss any subject matter concerning the above application via Internet e-mail communications. See MPEP 502.03. To approve such communications, Applicant must provide written authorization for e-mail communication by submitting the following statement via EFS-Web (using PTO/SB/439) or Central Fax (571-273-8300): Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. Written authorizations submitted to the Examiner via e-mail are NOT proper. Written authorizations must be submitted via EFS-Web (using PTO/SB/439) or Central Fax (571-273-8300). A paper copy of e-mail correspondence will be placed in the patent application when appropriate. E-mails from the USPTO are for the sole use of the intended recipient, and may contain information subject to the confidentiality requirement set forth in 35 USC § 122. See also MPEP 502.03. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Russell Negin, whose telephone number is (571) 272-1083. This Examiner can normally be reached from Monday through Thursday from 8 am to 3 pm and variable hours on Fridays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s Supervisor, Larry Riggs, Supervisory Patent Examiner, can be reached at (571) 270-3062. /RUSSELL S NEGIN/Primary Examiner, Art Unit 1686 28 February 2026
Read full office action

Prosecution Timeline

Dec 17, 2021
Application Filed
Aug 26, 2025
Non-Final Rejection — §112
Dec 23, 2025
Response Filed
Feb 28, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603146
MULTIMODAL DOMAIN EMBEDDINGS VIA CONTRASTIVE LEARNING
2y 5m to grant Granted Apr 14, 2026
Patent 12603157
METHOD AND SYSTEM FOR EVALUATING MELT FRAGMENTATION IN SODIUM-COOLED FAST REACTOR (SFR)
2y 5m to grant Granted Apr 14, 2026
Patent 12590948
SYSTEMS AND METHODS FOR DISCOVERY AND ANALYSIS OF MARKERS
2y 5m to grant Granted Mar 31, 2026
Patent 12582475
HYBRID SIMULATION MODEL FOR SIMULATING MEDICAL PROCEDURES
2y 5m to grant Granted Mar 24, 2026
Patent 12573486
METHOD AND SYSTEM FOR IDENTIFYING FASTING AND POSTPRANDIAL PERIODS BASED ON DETECTED EVENTS AND USING THE SAME TO TRAIN A MATHEMATICAL MODEL
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
89%
With Interview (+33.3%)
4y 1m
Median Time to Grant
Moderate
PTA Risk
Based on 899 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month